Inhibrx Biosciences, Inc.
INBX
$89.84
$0.740.83%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.44M | -32.83M | -35.26M | -28.65M | -43.31M |
| Total Depreciation and Amortization | 537.00K | 564.00K | 583.00K | 661.00K | 675.00K |
| Total Amortization of Deferred Charges | 732.00K | 642.00K | 638.00K | 626.00K | 533.00K |
| Total Other Non-Cash Items | 3.14M | 3.22M | 3.63M | 3.21M | 2.88M |
| Change in Net Operating Assets | -8.99M | -1.72M | -3.42M | -5.80M | 3.32M |
| Cash from Operations | -38.03M | -30.12M | -33.82M | -29.95M | -35.90M |
| Capital Expenditure | -- | 0.00 | -10.00K | 0.00 | -21.00K |
| Sale of Property, Plant, and Equipment | -- | 0.00 | 3.00K | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | 0.00 | -7.00K | 0.00 | -21.00K |
| Total Debt Issued | 74.99M | 0.00 | 0.00 | 0.00 | 99.97M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 471.00K | 1.25M | 352.00K | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 0.00 | 0.00 | 0.00 | -125.00K |
| Cash from Financing | 75.46M | 1.25M | 352.00K | 0.00 | 99.84M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 37.44M | -28.87M | -33.48M | -29.95M | 63.92M |